3-V Biosciences, Inc.: Series B $30M

Posted in I - Series B, Q - 3Q09, R - WEST, X - Antiviral, X - RNAi, XX - CA

3-V Biosciences (Palo Alto, CA) a preclinical-stage biopharma company focused on broad-spectrum antivirals for respiratory viral infections, closed a $30M Series B financing. Participants include New Enterprise Associates, The Column Group and Kleiner Perkins Caulfield & Byers.

Traversa Therapeutics, Inc.: Series B $5M

Posted in I - Series B, Q - 2Q09, R - WEST, X - Device (Delivery), X - RNAi, X - THx Delivery, XX - CA

Traversa Therapeutics (La Jolla, CA) a preclinical-stage biopharmaceutical company developing RNAi delivery technologies, closed a $5M Series B financing. Participants include Morningside, Mesa Verde Venture Partners and Tech Coast Angels.

Intradigm Corp.: Series B $2.9M

Posted in I - Series B, Q - 1Q09, R - WEST, X - Oncology, X - RNAi, XX - CA

Intradigm (Palo Alto, CA) an early-stage developer of RNAi therapeutics with an initial focus on oncology, closed a $2.9M Series, bringing the round total to $21.4M. Participants include Astellas Venture Management, Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund and Novartis Venture Funds.

Prosensa, BV: Series B $25.0M

Posted in I - Series B, Q - 4Q08, R - INTERNATIONAL, X - Muscular Dystrophy, X - RNAi

Prosena (The Netherlands) developer of RNA-based splice modulating therapeutics closed a $25M Series B financing. Participants include GIMV, AGF Management, Abingworth Management, Life Sciences Partnersand MedSciences Capital.

Intradigm Corp.: Series B $18.5M

Posted in I - Series B, Q - 4Q08, R - WEST, X - Oncology, X - RNAi

Intradigm (Palo Alto, CA) early-stage developer of RNAi-based oncology therapeutics, closed a $18.5M Series B financing. Participants include Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund and Novartis Venture Fund.

Biomics Biotechnologies, Inc.: Series B $5M

Posted in I - Series B, Q - 3Q08, R - INTERNATIONAL, X - RNAi, X - Target ID

Biomics Biotechnologies (China) development-stage company focused on target identification and RNAi therapeutics, closed a $5M Series B financing. Participants include Jiangsu Dinghong Venture Capital and Jiangsu Benefit Rise Group.

Expression Genetics, Inc.: Series B $12M

Posted in I - Series B, Q - 3Q08, R - SOUTH EAST, X - Cardiology, X - Oncology, X - RNAi

Expression Genetics (Huntsville, AL) development-stage specialty biopharmaceutical company specializing in cancer immunotherapies for ovarian and cardiovascular disease, closed a $12M Series B financing. Participants include ?

Dicerna Pharmaceuticals, Inc.: Series A $8.4M

Posted in I - Series A, Q - 3Q08, R - NORTH EAST, X - Diabetes, X - Endocrinology, X - Oncology, X - RNAi

Dicerna Pharmaceuticals (Watertown, MA) clinical-stage biopharmaceutical company developing RNAi therapeutics for multiple clinical applications, closed a $8.4M Series A. Participants include Abingworth, Oxford Bioscience Partners and Skyline Ventures.

Miragen, Inc.: Series A $8M

Posted in I - Series A, Q - 2Q08, R - ROCKY MOUNTAIN, X - Cardiology, X - RNAi, X - miRNA

Miragen (Boulder, CO) development-stage company focused on the treatment of cardiovascular and muscle disease based on microRNA biology, closed a $8M Series A financing. Participants include Atlas Venture and Boulder Ventures.

Quark Pharmaceuticals, Inc.: Series B $27M

Posted in I - Series B, Q - 2Q08, R - WEST, X - Opthalmology, X - RNAi, X - Renal

Quark Pharmaceuticals (Fremont, CA) development-stage pharmaceutical company focused on discovering and developing novel RNAi therapeutics, closed a $27M Series B financing. Participants include SBI Investment Co.

« Previous Entries

to top of page...